Here’s one thing you can take to the bank when talking about penny stocks: there is a ton of potential risk, but there is also a ton of potential reward. For the most part, timing is the key. Now, that doesn’t mean timing on just buying/selling a penny stock, it could mean timing on research. Did you see the specific news or Tweet that came out on a penny stock at the best moment? Did you see the filing before the rest of the market did?
Sometimes, but not all the time, penny stocks can get a bad rap. Many traders think they are not as profitable as blue chips. That can be a fair argument, but as we’ve seen time and time again, some penny stocks have been able to produce strong triple-digit, or 1,000%+ short-term runs. That said, a good majority of those big movers were ones that teetered back and forth for weeks before breaking out.
The whole reason I bring this up is because that these highly volatile penny stocks might require a little more research than others. It doesn’t hurt to research these ideas to find ones that have a solid foundation. It might help significantly to only put stocks on your watch-list that have a history of maintaining a steady, sturdy growth. Check these handful of penny stocks out today and get them on your radar for the short-term. Each has solid news out recently and could be a major mover short-term.
Check Out This Top Penny Stock Idea For Tuesday: Immuron Limited
Immuron Limited (Nasdaq: IMRN), a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company markets Travelan for the prevention of travellers’ diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease; and IMM-529, a clinical stage product for clostridium difficile infections.
Immuron Limited provided shareholders with an update on the company’s research collaboration with the Naval Medical Research Center (NMRC) to develop and clinically evaluate a new therapeutic against campylobacter and ETEC (E-Coli). The NMRC recently requested a Pre-IND meeting with the U.S. Food and Drug administration (FDA) regarding its new investigational drug which the company is developing to treat moderate to severe campylobacteriosis and ETEC infections.
The FDA on the 26 May 2020 issued guidance explaining how the coronavirus disease public health emergency is impacting the conduct of formal meetings and its review of certain user fee-funded applications. The FDA will focus its resources on applications and submissions related to COVID-19 and other life-threatening conditions. The FDA will still aim to conduct initial investigational new drug application (IND) 30-day safety reviews and respond to “other important safety issues that may emerge during IND development”. The agency will provide written comments on the non-clinical information in the Pre-IND information package which is planned to be submitted on the 10th of June 2020. Following the FDA’s guidance and feedback, the NMRC plans to file an investigational new drug (IND) application later this year and commence the Phase 2 clinical studies during the first half of 2021.
“We received a formal start work notification and approval at the end of January 2020 from the Henry Jackson Foundation for the Advancement of Military Medicine to commence work on the sub award,” said Dr. Jerry Kanellos, CEO of Immuron Ltd.
“The Australian Importation permit required to ship the vaccines from the NMRC was approved by Biosecurity Australia and the NMRC vaccines were shipped to our contract research partner to commence the project. The COVID-19 pandemic put the brakes on this and all our research and development activities. We have been monitoring the situation closely and I am please to say with the easing of restrictions around Australia work on the development of the clinical product can now recommence. The plan is to have the product completed by the end of this year and have it ready for clinical evaluation next year.”
Check Out This Top Penny Stock Idea For Tuesday: Ideanomics, Inc.
Ideanomics, Inc. (Nasdaq: IDEX) focuses on monetizing the adoption of commercial electric vehicles, associated energy consumption, and developing financial services and Fintech products.
Ideanomics announced the commencement of electric taxi deliveries for Guilin, Guanxi Province. In November 2019, Ideanomics announced that its Mobile Energy Global (MEG) division secured an order for 2,300 electric taxis from the City of Guilin in Guanxi province through MEG’s partner QuianXi.
Ideanomics now expects delivery of the first 200 EV taxis within July 2020, beginning immediately and completing within the next three to four weeks. This order of will be comprised of Dongfeng Nissan Sylphy ZE vehicles, a regional version of the midsize sedan also known as the Nissan Sentra in other markets. The Sylphy is the best-selling Nissan model in China. The balance of order announced in November 2019 is expected to be delivered through the end of the year and will likely involve multiple manufacturers.
The initial 200 electric taxi delivery is valued at approximately RMB 20 Million or USD 2.8 Million. Ideanomics anticipates these vehicles will be booked on a gross basis, subject to the terms of the executed sales contract and in accordance with U.S. GAAP.
“As China’s economy recovers and businesses gradually resume operations, Ideanomics continues to execute on its business plans and grow its EV business,” said Ideanomics CEO Alf Poor. “We are pleased to announce this delivery and expect to build sales momentum throughout the year while redirecting resources from non-core businesses to help support growth in MEG.”
Check Out This Top Penny Stock Idea For Tuesday: Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and COVID-19. The Company’s lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Piclidenoson has been approved for a pilot clinical trial in Israel to treat COVID-19 infected patients with moderate-to-severe symptoms.
Can-Fite BioPharma Ltd. announced that in response to Can-Fite’s Pre-Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA), the FDA has provided detailed comments regarding the prospective use of Piclidenoson to treat patients suffering from COVID-19. The FDA’s response allows Can-Fite to proceed to the next step of formally submitting an IND for Piclidenoson in this indication.
Can-Fite CEO, Dr. Pnina Fishman commented, “We are grateful for the thoughtful and comprehensive guidance from the FDA. Using the FDA’s feedback on our clinical trial, we anticipate submitting an IND shortly. We believe that Piclidenoson’s anti-viral, anti-inflammatory, anti-rheumatic properties and excellent safety profile make it a strong candidate for the potential treatment of COVID-19.”
The planned Phase II trial will evaluate the efficacy and safety of Piclidenoson, when added to the current standard of care treatment, for COVID-19 infected patients with moderate-to-severe symptoms.
Piclidenoson, an A3 adenosine receptor (A3AR) agonist, has a well-established safety profile in clinical studies in the U.S. and abroad, and has been dosed in over 1,000 patients for the treatment of rheumatoid arthritis and psoriasis. The use of A3AR agonists as potent anti-inflammatory agents in addition to standard of care in acute infectious diseases where host defense responses are overwhelming, leading to cytokine storm and death, is supported by several peer reviewed studies, as well as by Can-Fite’s own work in the field of adenosine biology. A3AR agonists have been shown to be effective in models of inflammation and sepsis.